AZD-6482

AZD-6482 is a potent, selective, and ATP competitive small molecule inhibitor of phosphatidylinositol 3 kinase beta (PI3Kβ). It exhibits high selectivity for PI3Kβ over other class I PI3K isoforms and acts as an antithrombotic agent by inhibiting platelet aggregation without significantly affecting normal hemostasis. The drug was developed primarily for the prevention of thrombosis in conditions such as atherosclerosis that can lead to myocardial infarction or stroke. Its mechanism involves targeting the PI3Kβ pathway in platelets to reduce clot formation. AZD‑6482 has been investigated in clinical trials up to phase II for indications including ischemic stroke and thrombosis[1][7][9].

Other names

2-[[(1R)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoic acid